Brain state prediction commercialization rules

1. Introduction

Brain state prediction is an emerging application of biotechnology, neuroscience, artificial intelligence and neurotechnology that involves analysing brain activity to estimate an individual's mental or cognitive condition. These technologies use tools such as electroencephalography (EEG), functional magnetic resonance imaging (fMRI), brain-computer interfaces (BCIs), neural sensors and machine-learning algorithms.

Brain state prediction systems may be used in medical diagnosis, neurological research, mental health monitoring, cognitive rehabilitation, educational research and commercial neurotechnology products.

Commercialisation of these technologies raises important legal and ethical concerns because brain activity may reveal highly sensitive information about an individual's mental processes, cognitive functioning, emotional responses and neurological conditions.

For example, a commercial neurotechnology company may develop an EEG-based system that estimates attention levels or cognitive workload. Although such technology may provide medical or research benefits, its use for employee monitoring, behavioural profiling or commercial prediction creates privacy and discrimination concerns.

Therefore, brain state prediction commercialization requires a regulatory framework addressing informed consent, neural data protection, medical device regulation, scientific accuracy, cybersecurity and commercial accountability.

2. Meaning and scope of brain state prediction commercialization

Brain state prediction commercialization refers to the development, marketing, licensing and commercial use of technologies that analyse neural signals to estimate or predict an individual's brain-related conditions.

These technologies generally operate through three stages:

Neural data collection: Brain signals are collected through EEG devices, neuroimaging equipment or other neural interfaces.

Data processing: Artificial intelligence and computational algorithms analyse the collected signals.

Prediction and application: The system generates an estimate concerning cognitive activity, neurological conditions or other brain-related states.

Major commercial applications include:

Neurological disease diagnosis and monitoring.

Cognitive rehabilitation technologies.

Brain-computer interface products.

Medical research and clinical applications.

Mental workload assessment.

Neurotechnology-based healthcare services.

Research into cognitive performance.

Commercialisation must distinguish between clinically validated medical applications and experimental consumer products. A system claiming to diagnose a neurological disorder may attract substantially different regulatory requirements from a consumer device providing general cognitive feedback.

3. Legal framework governing brain state prediction commercialization in India

India does not currently have one dedicated statute specifically regulating the commercialisation of brain state prediction technologies. Their regulation depends on the nature of the technology, the data processed and its intended application.

A. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023, establishes India's legal framework for processing digital personal data.

Brain state prediction companies may collect information linked to identifiable individuals through neural sensors, medical applications and connected devices.

Important compliance requirements include:

Processing personal data according to applicable legal requirements.

Providing appropriate information about data processing.

Obtaining valid consent where consent is the applicable legal basis.

Implementing reasonable security safeguards.

Providing prescribed personal data breach notifications.

Respecting applicable data principal rights.

The Act does not create a separate statutory category called neural data. However, identifiable neural information can constitute personal data and must be handled according to applicable requirements.

B. Information Technology Act, 2000

The Information Technology Act provides the legal framework for electronic records, cybersecurity and certain computer-related offences.

Section 43 addresses unauthorised access and specified damage to computer systems.

Section 66 addresses certain computer-related offences involving dishonest or fraudulent conduct.

Section 70B establishes the Indian Computer Emergency Response Team (CERT-In).

These provisions are relevant to commercial neurotechnology platforms that collect and process neural information through digital systems.

C. Medical Devices Rules, 2017

The Medical Devices Rules, 2017, regulate medical devices under the Drugs and Cosmetics Act, 1940.

Brain state prediction systems intended for medical purposes may fall within the medical device regulatory framework depending on their intended use and classification.

Examples include:

EEG-based diagnostic systems.

Neurological monitoring devices.

Medical brain-computer interfaces.

Software intended to support neurological diagnosis.

Manufacturers must comply with applicable licensing, quality management, safety and performance requirements.

Not every consumer neurotechnology product automatically qualifies as a medical device. Its intended purpose and regulatory classification are important.

D. Consumer Protection Act, 2019

The Consumer Protection Act regulates unfair trade practices, misleading advertisements and defective products.

Commercial neurotechnology companies must avoid making unsupported claims about their ability to detect thoughts, emotions, intelligence or neurological disorders.

Companies marketing brain state prediction products must provide accurate information concerning scientific validation, limitations and intended applications.

E. Constitution of India

Article 21 protects life and personal liberty, including the fundamental right to privacy recognised by the Supreme Court.

Article 14 guarantees equality before the law.

These constitutional protections are relevant where brain state prediction technologies are used in ways that interfere with individual privacy, autonomy or equal treatment.

4. International legal and regulatory framework

A. UNESCO Recommendation on the Ethics of Neurotechnology, 2025

UNESCO's Recommendation on the Ethics of Neurotechnology, adopted in November 2025, provides an important international ethical framework for responsible neurotechnology development and use.

It addresses concerns relating to human dignity, mental privacy, autonomy, informed consent, equality and protection against misuse of neural information.

It is particularly relevant to commercial neurotechnology companies developing brain monitoring and prediction products.

The Recommendation is a normative international instrument rather than a directly enforceable Indian statute.

B. OECD Recommendation on Responsible Innovation in Neurotechnology, 2019

The OECD recommendation establishes principles for responsible neurotechnology innovation.

It encourages governments and developers to consider safety, privacy, scientific integrity, transparency and accountability.

It is relevant to companies commercialising brain-computer interfaces and neural prediction technologies.

C. European Union General Data Protection Regulation, 2016

The GDPR regulates personal data processing within its applicable territorial scope.

Article 9 provides additional protection for specified sensitive categories, including health data and genetic data.

Neural data may qualify as health data or another protected category depending on the information and processing context.

Commercial neurotechnology companies operating within the GDPR's scope must comply with applicable privacy requirements.

D. European Union Artificial Intelligence Act, 2024

The EU AI Act establishes a risk-based regulatory framework for artificial intelligence systems.

Certain AI applications involving employment, education, biometric categorisation and other sensitive contexts may attract additional restrictions or high-risk requirements.

Its provisions are relevant to commercial brain state prediction systems where AI is used to evaluate individuals or influence significant decisions.

5. Major regulatory requirements for commercialisation

A. Informed consent

Companies must ensure that individuals understand what neural information is being collected, how it will be processed and whether it will be shared with third parties.

Consent arrangements should clearly distinguish medical treatment, scientific research and commercial exploitation.

B. Neural data privacy

Neural information may reveal sensitive details about cognitive activity and neurological health.

Commercial organisations should establish strict access controls, encryption, retention policies and appropriate data-sharing restrictions.

C. Scientific validation

Brain state prediction products must undergo appropriate scientific testing before making clinical or commercial claims.

Manufacturers should establish the accuracy, reliability, limitations and intended applications of their prediction systems.

D. Medical device approval

Where a brain state prediction system qualifies as a medical device, manufacturers must obtain the relevant regulatory permissions and comply with applicable quality and safety requirements.

E. Algorithmic transparency

Companies should provide appropriate information about the purpose, limitations and reliability of their prediction algorithms.

This is particularly important where predictions may influence medical treatment, employment or educational decisions.

F. Commercial advertising

Manufacturers must not make misleading claims concerning their ability to identify thoughts, emotions, intelligence or neurological conditions.

Commercial claims should be supported by adequate scientific evidence.

6. Important judicial decisions and case laws

There are currently no widely established Indian Supreme Court judgments specifically addressing the commercialisation of brain state prediction technologies. However, several judicial decisions provide important constitutional and legal principles for regulating neurotechnology.

A. Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1

The Supreme Court recognised privacy as a fundamental right under Article 21 and Part III of the Constitution.

The judgment established that privacy includes informational privacy and protection against unjustified interference with personal information.

Relevance: Neural data may reveal highly sensitive information concerning an individual's neurological condition and cognitive activity. Commercial brain state prediction companies must therefore adopt strong privacy protections and ensure lawful processing of personal information.

B. Selvi v. State of Karnataka (2010) 7 SCC 263

The Supreme Court examined the constitutional validity of involuntary narco-analysis, polygraph examinations and brain electrical activation profile tests.

The Court emphasised the importance of personal liberty, mental privacy and protection against involuntary testimonial techniques.

It held that involuntary administration of the techniques in question violated constitutional protections under Articles 20(3) and 21.

Relevance: This judgment is particularly significant for neurotechnology because it establishes constitutional limits on the involuntary use of techniques that examine or seek to infer information from mental processes.

Commercial brain state prediction should therefore respect individual autonomy and must not be used to justify coercive mental examination.

C. K.S. Puttaswamy v. Union of India (Aadhaar) (2019) 1 SCC 1

The Supreme Court examined privacy, proportionality and the permissible use of personal information in the Aadhaar framework.

The judgment discussed the importance of protecting personal data and ensuring that state action satisfies constitutional requirements.

Relevance: Commercial neurotechnology platforms should collect only information necessary for their stated purposes and implement appropriate safeguards against excessive data collection.

D. Shreya Singhal v. Union of India (2015) 5 SCC 1

The Supreme Court examined the constitutional validity of Section 66A of the Information Technology Act and emphasised the importance of freedom of expression and constitutional safeguards in digital regulation.

Relevance: Commercial neurotechnology platforms must operate within the applicable constitutional and digital regulatory framework. Their regulation should protect individuals without relying on arbitrary restrictions.

E. Common Cause v. Union of India (2018) 5 SCC 1

The Supreme Court recognised the importance of individual autonomy and dignity in decisions concerning medical treatment and end-of-life care.

The judgment discussed informed consent and the right of individuals to make important decisions concerning their bodies and medical treatment.

Relevance: Brain state prediction systems used in medical treatment and neurological monitoring should respect patient autonomy, informed consent and individual dignity.

7. Ethical and regulatory challenges

Commercial brain state prediction creates several important legal and ethical concerns.

Mental privacy: Neural information may reveal sensitive details about individuals that they did not intend to disclose.

Scientific reliability: Prediction algorithms may generate inaccurate or misleading conclusions.

Commercial exploitation: Companies may monetise neural information without adequate transparency.

Discrimination: Employers or educational institutions may misuse predicted cognitive states to evaluate individuals unfairly.

Informed consent: Individuals may not fully understand the implications of neural data collection.

Cybersecurity: Neural databases may become targets of unauthorised access and data theft.

Algorithmic bias: Prediction systems may produce different levels of accuracy across populations.

Regulatory uncertainty: Existing laws do not provide a comprehensive, technology-specific framework for commercial neural data applications.

8. Suggestions for strengthening the regulatory framework

India should develop a comprehensive regulatory approach to the commercialisation of neurotechnology and brain state prediction systems.

Important measures include:

Establishing specific safeguards for neural information.

Developing standards for scientific validation of brain state prediction products.

Requiring appropriate regulatory approval for medical neurotechnology devices.

Strengthening informed consent procedures.

Prohibiting deceptive commercial claims concerning mental-state detection.

Establishing independent audits of high-impact prediction algorithms.

Preventing discriminatory use of neural predictions in employment and education.

Introducing strong cybersecurity standards for neural databases.

Promoting ethical oversight of commercial neuroscience research.

Strengthening coordination between health, biotechnology and data protection regulators.

9. Conclusion

Brain state prediction commercialisation represents an important development in biotechnology, neuroscience and artificial intelligence. It offers opportunities for neurological diagnosis, cognitive rehabilitation, medical research and advanced brain-computer interfaces.

However, commercial use of these technologies creates significant concerns involving mental privacy, informed consent, scientific accuracy, algorithmic discrimination and individual autonomy.

In India, the Digital Personal Data Protection Act, 2023, Information Technology Act, 2000, Medical Devices Rules, 2017 and constitutional protections under Article 21 provide important elements of the applicable legal framework.

Judicial decisions such as Selvi v. State of Karnataka, Justice K.S. Puttaswamy v. Union of India and Common Cause v. Union of India establish important principles concerning mental privacy, personal autonomy and informed consent.

Ultimately, commercialisation of brain state prediction technologies must balance scientific innovation with constitutional rights and ethical responsibilities. A dedicated regulatory framework should protect neural information, ensure scientific reliability and prevent the misuse of technologies capable of analysing human brain activity.